Ignite Creation Date:
2024-05-06 @ 7:01 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05860465
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2023-05-08
Brief Title:
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Sponsor:
Shanghai Pharmaceuticals Holding Co Ltd
Organization:
Shanghai Pharmaceuticals Holding Co Ltd
Study Overview
Official Title:
A Phase IIIII Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positive HER2-negative Locally Advanced or Metastatic Breast Cancer That Progressed on CDK46 Inhibitor Combined With Endocrine Therapy
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK46 inhibitor combined with endocrine therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None